PLCG2 and B-cell chronic lymphocytic leukemia: A high burden of <i>BTK</i> and <i>PLCG2</i> mutations was found only in patients with the favorable transition pattern, suggesting that removing BTK inhibition might be particularly harmful if CLL cells are progressing through mechanisms external to the BTK axis.